



# BETA DRUGS LIMITED

Date: 19<sup>th</sup> October 2024

The Listing Manager,  
National Stock Exchange of India Limited  
Exchange Plaza, Bandra-Kurla Complex,  
Bandra (E),  
Mumbai – 400 051

NSE Code: BETA

Dear Sir/Madam,

**Sub: Disclosure(s) and outcome of Board meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements), 2015.**

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“**Listing Regulations**”), we wish to inform you that the Board of Directors (“**Board**”) of the Company at its meeting held today i.e., 19 October 2024 has, *inter alia*, taken the following decisions:

- (a) Approving the alteration of the memorandum of association of the Company to increase the authorized share capital of the Company;
- (b) Approving the issue and offer of Equity shares and compulsorily convertible debentures of the Company (“**CCDs**”) on a preferential basis; and
- (c) Issuing a Notice convening an extra-ordinary general meeting on 12 November 2024 for, *inter alia*, seeking shareholders’ approval for *inter alia* matters listed out in (a) and (b) above, and such other matters as listed out as part of the **Annexure**.

The details regarding the aforesaid items, as required under Regulation 30 and Schedule III of the Listing Regulations read with the SEBI circular no. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 (“**SEBI Circular**”), are provided in the **Annexure** below.

The meeting of the Board commenced at 12:30 P.M. and concluded at 5:00 P.M..

You are requested to take the same on your record.

Yours faithfully,

For Beta Drugs Limited

Company Secretary

**CIN No.:** L24230HP2005PLC028969

**Admin. Office :** SCO 184, Sector-5, Panchkula-134-114 Haryana (INDIA) Phone. +91-172-2585481-482-483

**Registered Office & Works:** Vill. Nandpur, Lodhimajra Road, Tehsil. : Baddi, Distt. Solan, H.P. Phone No. : 01795-236196

**Website :-** [www.betadrugslimited.com](http://www.betadrugslimited.com)

**E-Mail :-** [info@betadrugslimited.com](mailto:info@betadrugslimited.com)

## Annexure

### Part A

The details regarding alteration of the capital clause of the Memorandum of Association required to be disclosed as per Regulation 30 and Part of Schedule III of the Listing Regulations:

#	Particulars	Description
1.	Amendments to memorandum of association of listed entity, in brief.	Pursuant to the proposed increase in the authorised share capital of the Company, subject to the approval of the shareholders of the Company, it is proposed to alter the capital clause of the Company from INR 10,00,00,000 (Indian Rupees Ten Crore) divided into 1,00,00,000 (One Crore) equity shares of the Company (“ <b>Equity Shares</b> ”) of INR 10 (Indian Rupees Ten) each to 10,50,00,000 (Indian Rupees Ten Crore and Fifty Lakhs) divided into 1,05,00,000 (One Crore Five Lakh) Equity Shares of INR 10 (Indian Rupees Ten) each;

### Part B

The details regarding the issue and offer of compulsorily convertible debentures of the Company (“**CCDs**”) and equity shares of the Company (“**Equity Shares**”) on a preferential basis:

#	Particulars	Description																			
1.	Type of securities proposed to be issued	CCDs and Equity Shares																			
2.	Type of issuance	Preferential allotment on a private placement basis in accordance with the provisions of the Companies Act, 2013 and the rules made thereunder, Chapter V of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 (“ <b>ICDR Regulations</b> ”) and other applicable laws.																			
3.	Total number of securities proposed to be issued	7,07,651 CCDs and 100 Equity Shares																			
4.	Additional information in case of a Preferential Issue of CCDs and Equity Shares																				
i.	Name of the investor	(a) Healthquad Fund II (a scheme under Healthquad Trust II) (“ <b>Investor I</b> ”); (b) Inti Capital VCC – Inti Capital I (“ <b>Investor II</b> ”) (c) Generational Capital Breakout Fund 1 (“ <b>Investor III</b> ”)																			
ii.	Post allotment of securities - outcome of the subscription	Details of shareholding of Investor I and Investor II, prior to and after the proposed preferential issue, is as under: <table border="1" style="width: 100%; border-collapse: collapse;"> <thead> <tr> <th rowspan="2">Name of the Investor</th> <th colspan="2">Pre - Preferential allotment</th> <th colspan="2">Post-preferential allotment*</th> </tr> <tr> <th>No. of shares</th> <th>%</th> <th>No of Shares</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Investor I</td> <td>Nil</td> <td>Nil</td> <td>453,693</td> <td>4.40%</td> </tr> <tr> <td>Investor II</td> <td>Nil</td> <td>Nil</td> <td>211,721</td> <td>2.05%</td> </tr> </tbody> </table>	Name of the Investor	Pre - Preferential allotment		Post-preferential allotment*		No. of shares	%	No of Shares	%	Investor I	Nil	Nil	453,693	4.40%	Investor II	Nil	Nil	211,721	2.05%
Name of the Investor	Pre - Preferential allotment			Post-preferential allotment*																	
	No. of shares	%	No of Shares	%																	
Investor I	Nil	Nil	453,693	4.40%																	
Investor II	Nil	Nil	211,721	2.05%																	

		Investor III	14,000	0.15%	56,337	0.55%
		*Assuming full conversion of CCDs into equity shares of the Company on a 1:1 basis, subject to the terms of the CCDs				
iii.	Issue price/ allotted price (in case of convertibles)	INR 1,653.40				
iv.	Number of Investors	3 (three) investors				
5.	In case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument.	The tenure of CCDs shall be a maximum of 18 (eighteen) months from the date of the allotment. The CCDs shall be convertible into the equity shares of the Company anytime post expiry of 6 months from the date of allotment.				
6.	Whether proposed to be listed? If yes, name of the stock exchange(s);	CCDs will be unlisted. However, the equity shares to be issued and allotted pursuant to conversion of CCDs will be listed on National Stock Exchange of India Limited, subject to receipt of necessary permissions and approvals.				
7.	Tenure of the instrument - date of allotment and date of maturity	Up to 18 (eighteen) months from the date of allotment				
8.	Coupon/ interest offered, schedule of payment of coupon/interest and principal	A monthly coupon rate of 0.65% (zero point six five percent)				
9.	Charge/security, if any, created over the assets	No.				

### Part C

The details regarding the Notice convening the extra-ordinary general meeting on 12 November 2024.

#	Particulars	Description
1.	Date of Notice	19 October 2024
2.	Brief details viz. agenda (if any) proposed to be taken up, resolution to be passed, manner of approval proposed et	<p>(a) Approving the alteration of the memorandum of association of the Company to increase the authorized share capital of the Company by way of an ordinary resolution;</p> <p>(b) Approving the issue and offer of Equity Shares and CCDs of the Company on a preferential basis by way of a special resolution; and</p> <p>(c) Approving grant of special rights to Investor I and Investor II in accordance with Regulation 31B of the Listing Regulations by way of a special resolution.</p>